Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility.

Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation. E2F1, a canonical activator of cell-cycle genes, is sufficient to induce cell-cycle reentry from quiescence, but how it overcomes chromatin-mediated rep...

G. A. Lodewijk, Benjamin R. Topacio, Seung-Ho Lee et al. · 0 citations
Open access Sep 2026

A Unified 3D Generative Model for Synthesizable Structure-Based Drug Design

LDDM (Large Drug Discovery Model) is introduced, a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design, and a programmable design algorithm that enables accurate design of synthetically accessible compounds...

Ilia Igashov, Arne Schneuing, Adrian W. Dobbelstein et al. · 0 citations
Open access Aug 2026

Proteome-wide identification of the druggable CRBN interactome.

This pipeline identified 6 known and 43 novel CRBN-pomalidomide binders, including orthogonally validated hits that provide privileged starting points for MGD development, and expects this binding-focused workflow to be applicable to other MGD-E3 ligase systems, potentially extending the scope of this emerging drug cla...

Pius Galli, Shuhao Xiao, Y. Meng et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.